(4S)-PROTAC SOS1 degrader-1

MedChemExpress

®

| Cat. No.: | HY-144657 | |
|--------------------|---|----------|
| CAS No.: | 2913176-81-3 | |
| Molecular Formula: | C ₅₇ H ₇₆ CIFN ₁₀ O ₄ S | N. 5- |
| Molecular Weight: | 1051.79 | |
| Target: | PROTACs; Ras | |
| Pathway: | PROTAC; GPCR/G Protein | HN |
| Storage: | Please store the product under the recommended conditions in the Certificate of Analysis. | |

| BIOLOGICAL ACT | | | |
|---------------------------|--|---|--|
| Description | (4S)-PROTAC SOS1 degr | ader-1 is a potent PROTAC SOS1 degrader. (4S)-PROTAC SOS1 degrader-1 decreases the expression vel in a dose-dependent manner. (4S)-PROTAC SOS1 degrader-1 significantly inhibits the tumor | |
| IC ₅₀ & Target | K-RAS | | |
| In Vitro | (4S)-PROTAC SOS1 degrader-1 (compound 9d) (0.1, 1 μM) shows a potent SOSI degradation activity with an SOS1 protein degradation of 56.2 and 92.5% at 0.1 and 1 μM in NCI-H358 cells, respectively^[1]. (4S)-PROTAC SOS1 degrader-1 (24 h) degrades SOS1 in a dose- and time-dependent manner in NCI-H358 cells^[1]. (4S)-PROTAC SOS1 degrader-1 (9.8-2500 nM; 24 h) does not induce SOS2 and KRAS degradation in NCI-H358 cells^[1]. (4S)-PROTAC SOS1 degrader-1 (7.8-2000 nM; 24 h) decreases the expression of pERK and RAS-GTP level in NCI-H358 cells in a dose-dependent manner^[1]. MCE has not independently confirmed the accuracy of these methods. They are for reference only. Western Blot Analysis^[1] | | |
| | Cell Line: | NCI-H358 cells | |
| | Concentration: | 7.8, 15.6, 31.2, 62.5, 125, 250, 500, 1000, 2000 nM | |
| | Incubation Time: | 24 h | |
| | Result: | Showed a potent degradation activity with an EC_{50} of 98.4 nM in NCI-H358 cells. | |
| | RT-PCR ^[1] | | |
| | Cell Line: | NCI-H358 cells | |
| | Concentration: | 1 μM | |
| | Incubation Time: | 24, 48, 72 h | |
| | Result: | Showed the SOS2 mRNA level remained constant during the incubation period. | |
| | Cell Proliferation Assay [[] | 1] | |

| | Cell Line: | NCI-H358, MIA PaCa2, AsPC-1, SK-LU-1, SW620, A549 cells |
|---------|---|--|
| | Concentration: | 0-10000 nM |
| | Incubation Time: | 7 days |
| | Result: | Inhibited the cell growth with IC ₅₀ s of 0.525, 0.218, 0.307, 0.115, 0.199, 0.232 μM (EC ₅₀ s of 0.098, 0.255, 0.119, 0.104, 0.125, 0.022 μM)for NCI-H358, MIA PaCa2, AsPC-1, SK-LU-1, SW620, A549 cells, respectively. |
| | · · · · · · · · · · · · · · · · · · · | |
| In Vivo | safety profile ^[1] . | r-2 (10, 20 mg/kg; i.p., daily for 21 days) significantly inhibits the tumor growth in vivo with a good |
| n Vivo | safety profile ^[1] . | r-2 (10, 20 mg/kg; i.p., daily for 21 days) significantly inhibits the tumor growth in vivo with a good ently confirmed the accuracy of these methods. They are for reference only. BALB/c nude mice (NCI-H358 tumor xenografts) ^[1] |
| n Vivo | safety profile ^[1] . MCE has not independe | ently confirmed the accuracy of these methods. They are for reference only. |
| n Vivo | safety profile ^[1] . MCE has not independe Animal Model: | ently confirmed the accuracy of these methods. They are for reference only. BALB/c nude mice (NCI-H358 tumor xenografts) ^[1] |

REFERENCES

[1]. Zhou C,et al. Discovery of the First-in-Class Agonist-Based SOS1 PROTACs Effective in Human Cancer Cells Harboring Various KRAS Mutations. J Med Chem. 2022; 65(5):3923-3942.

Caution: Product has not been fully validated for medical applications. For research use only.

 Tel: 609-228-6898
 Fax: 609-228-5909
 E-mail: tech@MedChemExpress.com

 Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA